Industry
Biotechnology
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Loading...
Open
11.05
Mkt cap
924M
Volume
456K
High
11.13
P/E Ratio
-6.70
52-wk high
16.99
Low
10.77
Div yield
N/A
52-wk low
7.20
Portfolio Pulse from
December 12, 2024 | 4:00 pm
Portfolio Pulse from
November 26, 2024 | 4:00 pm
Portfolio Pulse from
November 15, 2024 | 3:30 pm
Portfolio Pulse from
November 13, 2024 | 8:00 pm
Portfolio Pulse from
November 13, 2024 | 2:00 pm
Portfolio Pulse from
November 05, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 2:22 pm
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 2:29 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.